CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.70
-0.21 (-2.65%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.91
Open7.83
Bid7.00 x 3200
Ask8.25 x 1000
Day's Range7.68 - 8.10
52 Week Range6.02 - 10.26
Volume322,948
Avg. Volume368,206
Market Cap421.274M
Beta (3Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-2.22
Earnings DateFeb 13, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND

    SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 29th International Symposium on.

  • GlobeNewswire10 days ago

    Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor

    Cytokinetics, Incorporated (CYTK) today announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose clinical trial of CK-3773274 (CK-274) in healthy adult subjects. CK-274 is a novel cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM). “The start of clinical trials for CK-274 marks an important milestone in our continuing innovation of potential sarcomere-directed medicines,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.

  • Benzinga12 days ago

    Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he isn't a fan of Netflix, Inc. (NASDAQ: NFLX ) because the content isn't as compelling as it once was. He sees it as a good story, but ...

  • GlobeNewswire18 days ago

    Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire18 days ago

    Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS

    Cytokinetics, Incorporated (CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial designed to assess the change from baseline in the percent predicted slow vital capacity (SVC) and other measures of skeletal muscle function after 12 weeks of treatment with reldesemtiv (formerly CK-2127107). In collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”), Cytokinetics is developing reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), as a potential treatment for people living with debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

  • GlobeNewswire18 days ago

    Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced five poster presentations at the 29th International Symposium on ALS/MND in.

  • Cytokinetics Sees Hammer Chart Pattern: Time to Buy?
    Zacks25 days ago

    Cytokinetics Sees Hammer Chart Pattern: Time to Buy?

    Cytokinetics has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswirelast month

    Cytokinetics to Participate in Upcoming Investor Conferences

    Cytokinetics, Incorporated (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018 at 10:20 AM MT at The Phoenician in Scottsdale, AZ, and to participate in a Fireside Chat at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 10:00 am ET at the Lotte New York Palace in New York. Additionally, members of Cytokinetics’ senior management team will also participate in the Global Mizuho Investor Conference on December 3-4, 2018 at the Lotte New York Palace in New York. The webcast replay of each presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CYTK earnings conference call or presentation 1-Nov-18 8:30pm GMT

    Q3 2018 Cytokinetics Inc Earnings Call

  • Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
    Zackslast month

    Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates

    Cytokinetics (CYTK) delivered earnings and revenue surprises of 24.53% and 377.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Cytokinetics: 3Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 40 cents. The biopharmaceutical company posted revenue of $10.6 million in the period. Cytokinetics shares ...

  • GlobeNewswirelast month

    Cytokinetics, Inc. Reports Third Quarter 2018 Financial Results

    METEORIC-HF Advancing to Trial Initiation FORTITUDE-ALS on Track to Complete Enrollment by Year End Phase 1 Clinical Studies of CK-274 and AMG 594 To Start in Q4 SOUTH SAN.

  • GlobeNewswire2 months ago

    Cytokinetics to Announce Third Quarter Results on November 1, 2018

    Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report third quarter results on November 1, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.

  • GlobeNewswire2 months ago

    Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day

    Cytokinetics, Incorporated (CYTK) plans to present an expansion of its development pipeline with the progression of two additional cardiac muscle directed drug candidates towards first-in-human clinical trials, at an R&D Day today in New York. The first, a novel cardiac troponin activator, discovered under its joint research program with Amgen, was the subject of an Investigational New Drug Application (IND) that Amgen recently filed with the Food & Drug Administration (FDA).

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Denny's, Cytokinetics, Beazer Homes, Heidrick & Struggles International, Equity Commonwealth, and Spok — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Benzinga2 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

    As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...

  • GlobeNewswire2 months ago

    Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program

    Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their collaborative skeletal muscle program, including clinical trial updates for reldesemtiv in neuromuscular and non-neuromuscular conditions. In addition to reldesemtiv, the companies are advancing another fast skeletal muscle troponin activator (FSTA) into Investigational New Drug (IND)-enabling studies and continuing their joint research program through 2019. Cytokinetics has been developing reldesemtiv as a potential treatment for people with Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), and other debilitating neuromuscular diseases and conditions associated with skeletal muscle weakness and/or fatigue.

  • GlobeNewswire2 months ago

    Cytokinetics to Host R&D Day on October 16, 2018

    Cytokinetics, Incorporated (CYTK), today announced that it will host an R&D Day on Tuesday, October 16, 2018 from 8:30 AM to 12:30 PM ET at the Parker New York Hotel in New York City. Members of Cytokinetics’ senior management will be joined by expert clinicians to provide new updates to the pipeline and review current clinical programs.

  • Simply Wall St.2 months ago

    Cytokinetics Incorporated (NASDAQ:CYTK): Risks You Need To Consider Before Buying

    If you’re interested in Cytokinetics Incorporated (NASDAQ:CYTK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...

  • GlobeNewswire3 months ago

    Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018-- Cytokinetics, Inc. today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Cantor Fitzgerald ...

  • Benzinga3 months ago

    Cantor Fitzgerald's 7 Buys For 7 Biotechs

    Cantor Fitzgerald has high hopes for patients with rare and orphan diseases.  “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...

  • Benzinga3 months ago

    The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...

  • Benzinga4 months ago

    Cytokinetics Downgraded On Data Delay

    Biopharma Cytokinetics Inc. (NASDAQ: CYTK ) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley.  The Analysts Morgan Stanley's Matthew Harrison ...